Dayvigo (Lemborexant) Geriatric Monitoring: What Clinicians and Patients 65+ Need to Know

Why Geriatric Monitoring for Lemborexant Differs From Younger Adults

Older adults metabolize drugs differently, carry more comorbidities, and face higher stakes from adverse events like falls. Lemborexant's dual orexin receptor antagonist (DORA) mechanism avoids some risks associated with benzodiazepine receptor agonists (BzRAs), but it does not eliminate the need for vigilant follow-up in patients aged 65 and older.

Age-related changes in renal clearance, hepatic blood flow, and body composition all shift pharmacokinetics. Glomerular filtration rate declines roughly 1 mL/min/year after age 40, meaning a 75-year-old patient may have 35% lower renal clearance than the midpoint of a Phase III population 1. Lemborexant is primarily metabolized by CYP3A4 and CYP3A5 with renal excretion playing a smaller role, so hepatic function and drug-drug interactions carry more clinical weight than creatinine alone 2. The FDA label states that no dose adjustment is needed for mild-to-moderate renal or hepatic impairment, but severe hepatic impairment (Child-Pugh C) is a contraindication.

Polypharmacy is the norm in this age group. The average American aged 65 to 79 takes four to five prescription medications 3. Each additional CNS-active drug multiplies the chance of excessive sedation, and CYP3A inhibitors (clarithromycin, itraconazole, certain HIV antiretrovirals) can double or triple lemborexant exposure. Monitoring in geriatric patients therefore means tracking the full medication list, not just the sleep prescription.

Baseline Assessments Before Starting Lemborexant

Before writing the first prescription, clinicians should establish a baseline snapshot that makes future changes measurable. This means documenting renal function, liver enzymes, cognitive status, gait stability, and the complete medication list in a single visit.

Renal and hepatic panels. A comprehensive metabolic panel (CMP) provides baseline eGFR, ALT, AST, and bilirubin. While lemborexant does not require renal dose adjustment, baseline eGFR helps interpret future lab shifts and flags patients whose declining kidney function could alter the clearance of co-prescribed drugs 2.

Cognitive screening. The Montreal Cognitive Assessment (MoCA) or Mini-Cog should be performed before starting any CNS-active medication in adults over 65. Insomnia itself impairs cognition, and separating drug effect from disease progression requires a documented starting point. The American Geriatrics Society (AGS) Beers Criteria recommend avoiding most sedative-hypnotics in older adults, and cognitive monitoring is a safeguard when a DORA is chosen as the least-risky pharmacologic option 4.

Fall-risk evaluation. A Timed Up and Go (TUG) test takes under two minutes and predicts fall probability. A score exceeding 12 seconds correlates with increased fall risk. Document this number. If the patient already scores above 14 seconds, the risk-benefit discussion around any sedative-hypnotic, including a DORA, deserves extra attention.

Medication reconciliation. List every prescription, over-the-counter product, and supplement. Flag CYP3A4 inhibitors (ketoconazole, clarithromycin, grapefruit juice in large quantities), CYP3A4 inducers (rifampin, carbamazepine, phenytoin), and other CNS depressants (opioids, benzodiazepines, gabapentinoids, muscle relaxants). Strong CYP3A4 inhibitors are contraindicated with lemborexant. Moderate CYP3A4 inhibitors require the dose to be capped at 5 mg 2.

SUNRISE-1: What the Key Trial Showed in Older Adults

The SUNRISE-1 trial specifically enrolled adults aged 55 and older (N=1,006) with insomnia, making it one of the few Phase III hypnotic trials designed around a geriatric-leaning population. Lemborexant 5 mg and 10 mg both improved latency to persistent sleep (LPS) and wake after sleep onset (WASO) versus placebo at one month 1.

The 5 mg dose reduced LPS by approximately 11 minutes versus placebo, and the 10 mg dose reduced it by about 16 minutes. WASO improved by roughly 20 minutes at 5 mg and 28 minutes at 10 mg. These are polysomnography-measured outcomes, not self-report, which adds reliability.

A head-to-head comparison arm against zolpidem extended-release 6.25 mg (the approved geriatric dose) showed that lemborexant preserved next-morning psychomotor function better than zolpidem. On the Digit Symbol Substitution Test (DSST) administered the morning after dosing, zolpidem ER impaired performance relative to placebo, while lemborexant 5 mg did not 1. This is a clinically meaningful distinction for older adults who need to drive, manage medications, or manage stairs each morning.

The trial excluded patients with severe hepatic impairment, unstable psychiatric illness, and moderate-to-severe sleep apnea (apnea-hypopnea index ≥15). Real-world geriatric patients frequently have one or more of these conditions, so the clean trial results require adjustment for clinical reality. Monitoring plans bridge this gap.

Fall Risk: The First 14 Days and Beyond

Falls are the leading cause of injury-related death in Americans over 65, with more than 36,000 fatal falls per year according to CDC data 5. Any drug that causes sedation, dizziness, or impaired balance increases this risk. Lemborexant's DORA mechanism produces less motor impairment than BzRAs, but "less" is not "none."

The highest-risk window is the first two weeks. Patients are adjusting to the drug, and nocturnal awakenings (which DORAs reduce but do not eliminate) combined with residual sleepiness create a dangerous combination when a patient rises to use the bathroom. A simple intervention: instruct patients to sit on the edge of the bed for 30 seconds before standing during the first month of therapy.

Structured follow-up. Schedule a phone or telehealth check at day 7 and an in-person visit at day 14. Ask three questions: (1) Have you fallen or felt unsteady? (2) Do you feel drowsy the morning after taking Dayvigo? (3) Are you sleeping at least 7 hours between the dose and when you need to be alert? If the answer to question 3 is no, the fall risk from residual sedation rises sharply.

After the initial two-week window, reassess fall risk quarterly using the TUG test. Any increase of 3 or more seconds from baseline warrants a medication review.

Renal and Hepatic Monitoring Schedule

Lemborexant does not require the serial renal monitoring that aminoglycosides or lithium demand, but geriatric patients on any chronic medication benefit from periodic lab surveillance. A practical schedule: CMP at baseline, 3 months, and then every 6 months.

The 3-month check catches early hepatic enzyme elevations. Post-marketing data have not revealed a hepatotoxicity signal for lemborexant, but CYP3A-metabolized drugs can occasionally cause idiosyncratic liver injury, and older adults are at higher risk 2. An ALT rise above 3 times the upper limit of normal should prompt discontinuation and further workup.

Renal function tracking matters less for lemborexant itself and more for the medication constellation around it. If eGFR drops below 30 mL/min/1.73m², review every co-prescribed drug for dose adjustment needs. A patient whose renal function was stable at 55 mL/min at baseline may decline to 40 mL/min over 18 months, and this decline affects gabapentin, metformin, and other common geriatric prescriptions more than it affects lemborexant directly.

Drug-Drug Interaction Surveillance

Older adults change medications frequently. A new antibiotic course, a cardiology consult adding diltiazem, or an oncology referral prescribing a CYP3A4 inhibitor can all alter lemborexant exposure overnight. Monitoring drug interactions is not a one-time event. It is continuous.

Absolute contraindication. Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir-boosted HIV regimens) are contraindicated with lemborexant 2. If one of these drugs becomes necessary, lemborexant must be held for the duration of therapy.

Dose cap scenario. Moderate CYP3A4 inhibitors (fluconazole, erythromycin, verapamil, diltiazem) require the lemborexant dose to be no higher than 5 mg. Patients already on 5 mg can continue, but those on 10 mg need a reduction.

Inducers. Strong CYP3A4 inducers (rifampin, phenytoin, carbamazepine) substantially reduce lemborexant levels and may render the drug ineffective. The FDA label recommends avoiding this combination 2.

CNS stacking. Opioids, benzodiazepines, gabapentinoids, and alcohol each compound sedation risk. The AGS Beers Criteria already flag most of these in older adults 4. When lemborexant is added to an existing CNS-active regimen, the prescriber should document the rationale, set a review date, and ideally taper the older agent.

Pharmacists performing medication therapy management (MTM) are a practical resource. Medicare Part D plans mandate MTM eligibility reviews, and patients on lemborexant plus two or more other chronic medications often qualify.

Monitoring for Next-Day Somnolence and Functional Impairment

The SUNRISE-1 data on next-morning DSST performance are encouraging but based on a controlled environment where patients had a full sleep opportunity 1. Real-world older adults may take lemborexant after 11 p.m. and rise at 5 a.m., leaving only 6 hours for drug clearance. With a terminal half-life of approximately 17 to 19 hours, lemborexant plasma levels at 6 hours post-dose remain clinically significant.

Driving assessment. Ask directly: "Do you drive? If yes, at what time do you first drive after taking Dayvigo?" Patients should allow a minimum of 7 to 8 hours between the dose and operating a vehicle. The FDA label carries a next-morning impairment warning for all DORAs.

Subjective sleepiness scales. The Epworth Sleepiness Scale (ESS) can be administered at baseline, 2 weeks, and every 3 months. An ESS score ≥10 on treatment may indicate the dose is too high, sleep opportunity is too short, or an underlying sleep disorder (particularly obstructive sleep apnea) is being masked rather than treated.

Functional markers. For patients living independently, ask about instrumental activities of daily living (IADLs): managing finances, preparing meals, and keeping appointments. A decline in IADLs after starting lemborexant warrants dose reduction or discontinuation, not attribution to "normal aging."

Deprescribing: When and How to Stop Lemborexant

The American Academy of Sleep Medicine (AASM) and AGS both recommend periodic reassessment of hypnotic therapy in older adults. Lemborexant does not carry a physical dependence profile comparable to benzodiazepines, but abrupt discontinuation can transiently worsen insomnia (rebound insomnia), which may lead patients to restart the drug unnecessarily.

90-day reassessment cycle. At each 90-day mark, ask: Is the insomnia still present without medication? Have non-pharmacologic strategies (CBT-I, sleep hygiene, stimulus control) been attempted or maintained? Is the patient willing to try a taper?

Taper protocol. For patients on 10 mg, reduce to 5 mg for 2 weeks, then attempt discontinuation. For patients on 5 mg, no intermediate dose is available. A practical approach is to prescribe every-other-night dosing for 1 to 2 weeks before stopping entirely. Monitor for rebound insomnia during the first 3 to 5 nights off the drug.

CBT-I integration. Cognitive behavioral therapy for insomnia remains the first-line treatment for chronic insomnia in older adults per the AASM clinical practice guideline 6. If CBT-I was not offered before starting lemborexant, the deprescribing conversation is an opportunity to initiate it. Digital CBT-I platforms (SHUTi, Sleepio) offer accessibility for patients unable to attend in-person sessions.

Dr. Andrew Krystal, a sleep researcher involved in DORA clinical trials, has noted: "The goal with any hypnotic in older adults should be the shortest effective duration. DORAs offer a better safety margin than older agents, but they are still medications with trade-offs" 1.

Special Populations Within the Geriatric Group

Not all patients over 65 carry the same risk profile. A healthy, active 66-year-old and a frail 88-year-old with dementia require fundamentally different monitoring intensities.

Frail elderly (Clinical Frailty Scale ≥5). These patients warrant 5 mg as the maximum dose, weekly fall-risk checks for the first month, and involvement of a caregiver in monitoring for next-day confusion or unsteadiness. If the patient lives alone and has no reliable daily contact, a DORA may carry unacceptable unsupervised risk.

Patients with mild cognitive impairment (MCI) or early dementia. Sleep disturbance is common in these populations, and insomnia worsens cognitive decline. Lemborexant has theoretical advantages over anticholinergic sleep aids (diphenhydramine, doxepin at higher doses) because it does not block muscarinic receptors 4. A 2022 review in Alzheimer's Research and Therapy suggested that orexin system modulation may interact with amyloid pathology, though clinical significance remains unproven 7. Monitor MoCA scores every 6 months in this subgroup.

Patients on anticoagulants. Lemborexant does not have a direct interaction with warfarin or direct oral anticoagulants (DOACs), but fall risk plus anticoagulation equals bleeding risk. The combination of a DORA and a DOAC is not contraindicated, but it demands meticulous fall prevention counseling. The AAFP recommends fall-risk assessment at every visit for anticoagulated patients over 65 8.

Building a Geriatric Lemborexant Monitoring Checklist

A reusable checklist standardizes what can otherwise be inconsistent follow-up. The following schedule applies to a typical geriatric patient starting lemborexant 5 mg.

Day 0 (start of therapy): CMP, MoCA or Mini-Cog, TUG test, complete medication reconciliation, sleep diary initiation, driving safety counseling.

Day 7 (phone/telehealth): Fall screen, subjective sedation assessment, ESS if possible, confirm adequate sleep opportunity (≥7 hours).

Day 14 (in-person): Repeat TUG, review sleep diary, assess whether 5 mg is effective or 10 mg dose increase is warranted, recheck medication list for new prescriptions.

Month 3: CMP, ESS, TUG, medication reconciliation, first deprescribing discussion, consider CBT-I referral.

Month 6 and every 6 months thereafter: CMP, MoCA or Mini-Cog, TUG, ESS, full medication reconciliation, deprescribing re-evaluation.

The Endocrine Society's 2020 guidelines on managing medications in older adults emphasize that no chronic medication should auto-renew without periodic review 9. This principle applies directly to lemborexant.

Recognizing Red Flags That Require Immediate Action

Most geriatric monitoring is routine surveillance. Some signals demand same-day or next-day response.

New-onset confusion or hallucinations. DORAs can rarely cause hypnagogic or hypnopompic hallucinations and sleep paralysis. In older adults with baseline cognitive vulnerability, these events may be mistaken for delirium or dementia progression 2. Hold lemborexant immediately if the event is distressing or recurrent.

Fall with injury. Any fall resulting in emergency department evaluation should trigger automatic lemborexant review. The drug may or may not have contributed, but the event resets the risk-benefit calculation.

New CYP3A4 inhibitor prescription. If a patient is hospitalized and started on clarithromycin or a similar strong CYP3A4 inhibitor, lemborexant must be held during the course.

Daytime sleepiness worsening despite adequate sleep opportunity. This pattern may indicate undiagnosed obstructive sleep apnea. The AASM recommends screening with the STOP-BANG questionnaire, and a score ≥5 warrants polysomnography 6. Treating sleep apnea alone may resolve the insomnia, rendering the hypnotic unnecessary.

Patients over 65 starting lemborexant 5 mg should receive their first TUG reassessment within 14 days, a CMP at 3 months, and a formal deprescribing discussion no later than day 90.